Health Care

Boston Scientific Scraps This Aortic Valve, Sticks To 2025 Outlook

Rocket Pharma's Gene Therapy Future Clouded By Regulatory Uncertainty

Elon Musk's Neuralink Hits $9 Billion Valuation With New Funding

Rocket Pharma's Gene Therapy Future Clouded By Regulatory Uncertainty

Elon Musk's Neuralink Hits $9 Billion Valuation With New Funding

Why Is Diagnostic Firm Hologic Stock Trading Higher On Tuesday?

Why Is Teva Stock Trading Higher On Tuesday?

Why Is Diagnostic Firm Hologic Stock Trading Higher On Tuesday?

Why Is Teva Stock Trading Higher On Tuesday?

With Trials In Motion, Cash To 2027, Can Kyverna's Next Data Drop Turn The Stock Around?

Why Is Rare Lung Disease-Focused Savara Stock Trading Lower On Tuesday?

Health Care Recent News

Analyst Bullish On Ultragenyx, Poised For Growth With Six Drug Approvals Expected By 2028

Ultragenyx sees rising revenue and analyst support as key drug launch approaches, with potential profitability projected for 2027.

Why These Healthcare Giants Could Face Pressure From Startups

The rise of new challengers is placing new pressure on publicly traded incumbents, which are deeply embedded in the traditional layers of healthcare.

Veru's Enobosarm Shows Muscle In Wegovy Combo Trial

Veru reports strong safety and efficacy for enobosarm added to semaglutide, showing reduced functional decline and muscle loss in older adults.

Why Is GSK Partner Spero Therapeutics Stock Skyrocketing On Wednesday?

GSK and Spero ended a Phase 3 trial early meeting efficacy goals in cUTIs, positioning its treatment as the first oral carbapenem in the U.S.

InflaRx Ends Lead Asset Development After Failed Study For Rare And Painful Skin Disease

InflaRx ends its Phase 3 trial of vilobelimab in pyoderma gangrenosum and shifts focus to INF904 amid efforts to extend its cash runway.

Eli Lilly's May Meltdown Is In History Books — Could June Seasonality Bring A Rebound?

Eli Lilly stock down 19% in May, on track for worst month since 2009. But June historically brings better fortune, with 67% chance of closing higher.

Breaking The Pain Barrier: Lilly's Acquisition Of SiteOne Aims For Opioid Alternatives

Eli Lilly to acquire SiteOne Therapeutics in a deal worth up to $1 billion, advancing the development of a potential non-opioid treatment for chronic pain.

Why Is NeuroPace Stock Falling After Epilepsy Treatment Study Data?

NeuroPace's RNS System trial showed a strong safety profile and subgroup efficacy in drug-resistant epilepsy, prompting FDA pathway discussions.

UnitedHealth Hits 2008-Era Oversold Levels As Citadel Advisors Sells, Fisher Buys

UnitedHealth Group (NYSE:UNH) is in technical trouble, with its stock falling 42% this year. Some hedge funds are selling, but others see a buying opportunity.

Robert F. Kennedy Jr. Says CDC Drops COVID Vaccine For 'Healthy' Pregnant Women, Children

RFK Jr. says the COVID-19 vaccine is no longer on the CDC's recommended schedule for healthy kids and pregnant women, though the official site still shows it listed.

AbbVie To Present Cancer Trial Data At Upcoming ASCO Event

AbbVie shares new data for Temab-A, ABBV-706, and PVEK across lung, colorectal, and blood cancers ahead of the ASCO oncology conference.

Liquidia Scores FDA Nod For Lung Disease Drug Yutrepia, Faces Legal Challenge

Liquidia gains FDA approval for Yutrepia to treat PAH and PH-ILD, with funding in place despite ongoing patent litigation with United Therapeutics

Rocket Pharma Reports Patient Death In Rare Disease Gene Therapy Trial, FDA Puts Clinical Hold

Rocket Pharmaceuticals halted its Danon disease gene therapy trial after a patient death, with the FDA placing the study on clinical hold for review.